Bruker provides cutting edge mass spectrometry and NMR solutions. Join us at this year’s Metabolomics 2021 Virtual Conference to meet our experts and learn more about how Bruker’s suite of solutions is advancing Metabolomics and Lipidomics research worldwide.
Evaluation of Post-Acute COVID-19 Syndrome using NMR Spectroscopy and Mass Spectrometry
Bruker Workshop: Guest Speakers Professor Jeremy Nicholson and Team, Australian National Phenome Center (ANPC), Murdoch University
Tuesday, June 22, 9:00 AM EDT/ 3:00 PM CEST/ 9:00 PM BJT
Employing multiple high field NMR spectroscopic and Mass Spectrometric Platforms, the ANPC provides an integrative analytical and systems framework for exploring the aetiopathogenesis of disease using principles that are scalable and translatable to any pathological condition. In the battle against SARS CoV-2 and COVID-19 we are faced with a dynamic and adaptable enemy and the ongoing challenge of unravelling the complex immunopathological drivers of the acute and persistent effects of the disease.
In the last 15 months the ANPC has been devoted to uncovering the deep systemic effects of COVID-19 using a combination of exploratory and targeted technologies to study the extreme immune-metabolic and phenotypic complexity of the disease. We have examined patient biofluids from a variety of international sources to create new diagnostic and prognostic modelling approaches for disease detection, severity prediction and long-term follow up studies. NMR and Mass spectrometric data on blood plasma and urine show that COVID-19 causes multiple organ damage that are partially independent of the primary respiratory features. These multi-organ system involvements are translationally important because they potentially contribute to the level of morbidity shown in individual patients and lead to multiple levels of clinical actionability in the hospital environment and for studying patient recovery trajectories.
A key concern now is the huge international medico-economic burden of “Post-Acute COVID-19 Syndrome” (PACS) and the problem of identifying long-term effects of the disease at the biochemical level to monitor and mitigate long term effects in individuals. Here the concepts of phenoconversion and phenoreversion are illustrated with respect to spectroscopic biomarker shifts at the univariate multivariate level. The COVID-19 pandemic crisis provides an exemplar for the use of spectroscopy, and metabolic and systems medicine approaches to describe the natural history of an emergent zoonotic disease and shines light on the pathways to prevention, treatment, and mitigation of this global disease threat.
To register, visit the Metabolomics Conference website.